Remuzon P, Bouzard D, Cesare P D, Essiz M, Jacquet J P, Kiechel J R, Ledoussal B, Kessler R E, Fung-Tomc J
Centre de Recherche Bristol-Myers Squibb, Lognes, Marne-La-Vallee, France.
J Med Chem. 1991 Jan;34(1):29-37. doi: 10.1021/jm00105a006.
A series of novel N-1-(mono-,-(di- and -(trifluoro-tert-butyl)quinolones and -naphthyridines has been prepared. Structure-activity relationship (SAR) studies indicated that the in vitro antibacterial potency was the following order: 1-(1,1-dimethyl-2-fluoroethyl) greater than 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl] greater than 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituents. In the quinolone series the monofluoro-tert-butyl derivatives were found to possess better in vitro antibacterial activity than the nonfluorinated-tert-butyl equivalents. In vivo PD50 values of the 1-fluoro-tert-butyl-substituted derivatives reflect pharmacokinetic behavior and incomplete oral absorption.
已制备出一系列新型的N-1-(单-、双-和三氟叔丁基)喹诺酮类和萘啶类化合物。构效关系(SAR)研究表明,体外抗菌效力顺序如下:1-(1,1-二甲基-2-氟乙基)>1-[1-甲基-1-(氟甲基)-2-氟乙基]>1-[1,1-(二氟甲基)-2-氟乙基]取代基。在喹诺酮系列中,发现单氟叔丁基衍生物比未氟化的叔丁基类似物具有更好的体外抗菌活性。1-氟叔丁基取代衍生物的体内PD50值反映了药代动力学行为和口服吸收不完全的情况。